JIUQUAN, China, Nov. 15, 2021 /PRNewswire/
-- Qilian International Holding Group Limited
(Nasdaq: QLI) (the "Company"), a China-based
pharmaceutical and chemical products manufacturer, announced
that the Company recently started, through its
subsidiary Gansu Qilianshan Pharmaceutical Co.,
Ltd. ("Gansu QLS"), developing a new drug, Vitacoenzyme
(the "Drug"), that aims to prevent gastric
cancer. Currently, Gansu QLS is in the process of
selecting and cultivating fungal strain. The Drug is expected
to be on the market within three years.
Vitacoenzyme is a therapeutic and nutritional compound designed
to promote cell growth, improve immunity, enhance the activity of
detoxification enzymes, prevent abnormal lipid metabolism, increase
the decomposition rates of many carcinogens in human bodies, and
promote excretion from human bodies. Vitacoenzyme has also shown
some positive effect on interfering and blocking carcinogenesis and
preventing cancer in the upper gastrointestinal tract. At present,
Vitacoenzyme is primarily used for treatment of chronic
gastritis, atrophic gastritis, superficial gastritis,
esophagitis, esophageal epithelial cell hyperplasia,
prevention of cancer due to cell hyperplasia, as well as the
adjuvant treatment of various types of hepatitis and the treatment
of riboflavin deficiency and other diseases with remarkable
clinical efficacy.
According to clinical trials led by the Institute of Biophysics
and Institute of Microbiology of the Chinese Academy of Sciences
that collaborated with the 301 Hospital and Hebei Cancer
Institute etc., Vitacoenzyme showed an effect in
relieving atrophic gastritis, esophageal and cardia epithelial
cell hyperplasia the pre-symptoms of gastric cancer and
esophageal cancer, without toxic effects or adverse reactions.
In China, chronic gastritis,
atrophic gastritis and other diseases are common among people,
which are typically caused by factors such as irregular diet,
exposure to chemical substances, infection of Helicobacter pylori,
long-term smoking and alcohol, and mental stress.
With more than 50 years of experience in preparations
production and over 30 years of development of biological
fermentation production technology experience, Gansu QLS has a
provincial-level enterprise technology center, jointly recognized
in 2015 by Department of Industry and Information Technology
of Gansu Province, Gansu
Provincial Development and Reform Commission, and Science and
Technology Department of Gansu
Province. Gansu QLS has well developed R&D facilities,
relatively extensive experience in biofermentation, and
comparatively high capability in fungal strain
optimization and cultivation, promotion of biological fermentation
technology and innovation in production technology.
Mr. Zhanchang Xin, Chairman of the Board of Directors and CEO of
the Company, commented, "The development of this Drug is based on
our observation that we believe the future market trend for it is
upward with tremendous demand potential. Thus, we will spare no
effort to conduct research and development on this Drug to meet its
market demand in the future and further serve the public health.
More importantly, we expect that after the launch of this
Drug, it could significantly contribute to the improvement of
our production capacity and performance in the future."
About Qilian International Holding Group Limited
Qilian International Holding Group Limited, headquartered
in Gansu, China, is a
pharmaceutical and chemical products manufacturer in China. It
focuses on the development, manufacture, marketing and sale of
licorice products, oxytetracycline products, traditional Chinese
medicine derivatives product, heparin product, sausage casings, and
fertilizers. The Company's products are sold in more than 20
provinces in China. For more information, visit the company's
website at http://qilianinternational.com/
Forward-Looking Statements
This announcement contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements other than statements
of historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, financial
needs and the successful construction of the pig by-product
processing project facility. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect its
future results in the Company's registration statement and in its
other filings with the SEC.
For more information, please contact:
Qilian International Holding Group Limited
Email: QLI@qlsyy.net
Related Links
http://ir.qlsyy.net/.
View original
content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-limited-announces-initiation-of-development-of-new-drug-for-gastric-cancer-prevention-301423841.html
SOURCE Qilian International Holding Group Limited